Last $20.08 USD
Change Today -1.02 / -4.83%
Volume 536.3K
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 11:34 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$21.26
Previous Close
$21.10
Day High
$21.29
Day Low
$19.74
52 Week High
01/21/14 - $38.50
52 Week Low
08/7/13 - $16.00
Market Cap
2.0B
Average Volume 10 Days
847.7K
EPS TTM
--
Shares Outstanding
97.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

No Related Businessweek News Found

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and database systems for mapping cellular pathways, as well as its computational modeling and simulation platform; LEAP, a proprietary laser-enabled analysis and processing technology; and mAbLogix, a proprietary antibody discovery platform that enables production of B-cell libraries for discovery of antibodies. It has collaborations with ZIOPHARM Oncology, Inc.; Elanco, Inc.; Fibrocell Science, Inc.; Oragenics, Inc.; Synthetic Biologics, Inc.; AquaBounty Technologies, Inc.; AmpliPhi BioSciences Corp.; Genopaver, LLC; and Soligenix, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in West Palm Beach, Florida.

223 Employees
Last Reported Date: 03/31/14
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Founder and Chief Science Officer
Total Annual Compensation: $499.2K
Chief Operating Officer
Total Annual Compensation: $1.2M
Senior Vice President of Energy & Chemicals S...
Total Annual Compensation: $191.0K
Executive Vice President of Scientific & Publ...
Total Annual Compensation: $485.3K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

Intrexon Corporation Appoints James S. Turley to Board of Directors

Intrexon Corporation announced the appointment of James S. Turley to its Board of Directors, effective April 16. Mr. Turley will occupy the board seat vacated by Thomas Reed, Ph.D., Founder and Chief Science Officer of Intrexon. Dr. Reed will continue to serve as Chief Science Officer. Mr. Turley is the former Chairman and Chief Executive Officer of Ernst & Young. He led the firm from 2001 until his retirement in June of 2013. Mr. Turley joined Ernst & Young in 1977 and held various positions there until being named Regional Managing Partner for the Upper Midwest in 1994, and for New York in 1998. He was named Deputy Chairman in 2000 and Chairman in 2001. He was on the board of Catalyst from 2001-2013, serving as its Chair from 2009-2013, and until his retirement was a member of the Business Roundtable and IBLAC (International Business Leaders Advisory Council for the Mayor of Shanghai), and was co-chair of Russia's Foreign Investment Advisory Council.

Intrexon Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Intrexon Corporation reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company’s total revenues were $7,143,000 against $6,569,000 a year ago. The increase was primarily the result of deferred revenue arising from additional collaborations signed during 2013 as well as revenues generated from research and development services provided by pursuant to all of Intrexon's collaborations. Operating loss was $17,726,000 against $12,303,000 a year ago. Net loss was $13,018,000 against $30,937,000 a year ago. Net loss attributable to Intrexon was $12,204,000 against $30,937,000 a year ago. Net loss attributable to common shareholders was $12,204,000 or $0.13 basic and diluted per share against $36,640,000 or $6.52 basic and diluted per share a year ago. LBITDA was $4,685,000 against $14,496,000 a year ago. Adjusted LBITDA was $7,162,000 or $0.07 basic and diluted per share against adjusted EBITDA of $19,668,000 or $0.27 basic and diluted per share a year ago. For the year, the company’s total revenues were $23,760,000 against $13,774,000 a year ago. Operating loss was $58,023,000 against $75,157,000 a year ago. Net loss was $40,908,000 against $81,874,000 a year ago. Net loss attributable to Intrexon was $38,980,000 against $81,874,000 a year ago. Net loss attributable to common shareholders was $57,371,000 or $1.40 basic and diluted per share against $103,868,000 or $18.77 basic and diluted per share a year ago. LBITDA was $39,162,000 against $25,510,000 a year ago. Adjusted LBITDA was $23,738,000 or $0.27 basic and diluted per share against $29,802,000 or $0.43 basic and diluted per share a year ago.

Intrexon Corporation Announces Formation of Joint Venture with Select Group of External Investors

Intrexon Corporation announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors, to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants. IEP's first target product is isobutanol for gasoline blending. Intrexon's biocatalyst approach to GTL bioconversion reduces energy use, production costs, and waste while producing a single high value product. The Intrexon platform offers significant economic advantages over traditional conversion platforms that rely on costly thermochemical catalytic processes, such as the Fischer-Tropsch method of carbon upgrading, or depend on available plant-based feedstocks. IEP will utilize natural gas as its feedstock, which is a far less expensive carbon source than biomass or sugar-based technologies. Through an Exclusive Channel Collaboration (ECC) agreement, IEP will pay Intrexon a $25 million technology access fee to leverage the Company's synthetic biology capabilities, including the UltraVector(R) platform, to further enhance the performance of a target biocatalyst. In addition, IEP, in which Intrexon owns a one-half interest, will invest up to $50 million dollars in program development costs. Simultaneously, Intrexon entered into securities purchase agreements with the external investors in IEP for the private placement of 972,004 shares of common stock at a price of $25.72 per share for gross proceeds of $25 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $20.08 USD -1.02

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $153.80 USD -2.30
MorphoSys AG €63.26 EUR -0.98
XOMA Corp $4.26 USD -0.19
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 86.2x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 78.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.